Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor for Patients with Chronic Myeloid Leukemia

References

• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648–1671. doi:10.1038/leu.2016.10427121688
   PubMed Web of Science ®Google Scholar
• Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94(Suppl 2):S107–S121. doi:10.1007/s00277-015-2325-z25814077
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Jabbour E, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011;29(23):3173–3178. doi:10.1200/JCO.2010.33.416921747082
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Nazha A, et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012;119(19):4524–4526. doi:10.1182/blood-2011-10-38896722431574
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Bonifacio M, Calistri E, et al. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. Leuk Res. 2013;37(11):1457–1460. doi:10.1016/j.leukres.2013.07.03723993428
   PubMed Web of Science ®Google Scholar
• Yamamoto E, Fujisawa S, Hagihara M, et al. European treatment and outcome study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci. 2014;105(1):105–109. doi:10.1111/cas.1232124450386
   PubMed Web of Science ®Google Scholar
• Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2017;31(3):593–601. doi:10.1038/leu.2016.24627568522
   PubMed Web of Science ®Google Scholar
• Baccarani M, Druker BJ, Branford S, et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the tyrosine kinase inhibitor optimization and selectivity (TOPS) study. Int J Hematol. 2014;99(5):616–624. doi:10.1007/s12185-014-1566-224658916
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398–2406. doi:10.1038/leu.2017.25328804124
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Gugliotta G, Breccia M, et al. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Am J Hematol. 2017;92(8):797–805. doi:10.1002/ajh.2477428466557
   PubMed Web of Science ®Google Scholar
• Nteliopoulos G, Bazeos A, Claudiani S, et al. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica. 2019;104(12):2400–2409. doi:10.3324/haematol.2018.20022031073075
   PubMed Web of Science ®Google Scholar
• Lauseker M, Bachl K, Turkina A, et al. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. Am J Hematol. 2019;94(11):1236–1243. doi:10.1002/ajh.2562831456269
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017;123(22):4391–4402. doi:10.1002/cncr.3086428743165
   PubMed Web of Science ®Google Scholar
• Radich JP, Deininger M, Abboud CN, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(9):1108–1135. doi:10.6004/jnccn.2018.007130181422
   PubMed Web of Science ®Google Scholar
• Evans TC, Jehle D. The red blood cell distribution width. J Emerg Med. 1991;9(Suppl 1):71–74. doi:10.1016/0736-4679(91)90592-41955687
   PubMedGoogle Scholar
• Patel KV, Semba RD, Ferrucci L, et al. Red cell distribution width and mortality in older adults: a meta-analysis. J Gerontol a Biol Sci Med Sci. 2010;65(3):258–265. doi:10.1093/gerona/glp16319880817
   PubMed Web of Science ®Google Scholar
• Perlstein TS, Weuve J, Pfeffer MA, Beckman JA. Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med. 2009;169(6):588–594. doi:10.1001/archinternmed.2009.5519307522
   PubMedGoogle Scholar
• Cavusoglu E, Chopra V, Gupta A, et al. Relation between red blood cell distribution width (RDW) and all-cause mortality at two years in an unselected population referred for coronary angiography. Int J Cardiol. 2010;141(2):141–146. doi:10.1016/j.ijcard.2008.11.18719144426
   PubMed Web of Science ®Google Scholar
• Tsuboi S, Miyauchi K, Kasai T, et al. Impact of red blood cell distribution width on long-term mortality in diabetic patients after percutaneous coronary intervention. Circ J. 2013;77(2):456–461. doi:10.1253/circj.cj-12-073023075764
   PubMed Web of Science ®Google Scholar
• Osadnik T, Strzelczyk J, Hawranek M, et al. Red cell distribution width is associated with long-term prognosis in patients with stable coronary artery disease. BMC Cardiovasc Disord. 2013;13(1):113. doi:10.1186/1471-2261-13-11324320974
   PubMed Web of Science ®Google Scholar
• Sánchez-Chaparro MA, Calvo-Bonacho E, González-Quintela A, et al. Higher red blood cell distribution width is associated with the metabolic syndrome: results of the ibermutuamur cardiovascular risk assessment study. Diabetes Care. 2010;33(3):e40. doi:10.2337/dc09-170720190288
   PubMedGoogle Scholar
• Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM program and the duke databank. J Am Coll Cardiol. 2007;50(1):40–47. doi:10.1016/j.jacc.2007.02.06717601544
   PubMed Web of Science ®Google Scholar
• Huang YL, Hu ZD, Liu SJ, et al. Prognostic value of red blood cell distribution width for patients with heart failure: a systematic review and meta-analysis of cohort studies. PLoS One. 2014;9(8):e104861. doi:10.1371/journal.pone.010486125133510
   PubMed Web of Science ®Google Scholar
• Bessman JD, Gilmer PR Jr, Gardner FH. Improved classification of anemias by MCV and RDW. Am J Clin Pathol. 1983;80(3):322–326. doi:10.1093/ajcp/80.3.3226881096
   PubMed Web of Science ®Google Scholar
• Iriyama N, Hatta Y, Kobayashi S, et al. Higher red blood cell distribution width is an adverse prognostic factor in chronic-phase chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Anticancer Res. 2015;35(10):5473–5478.26408711
   PubMed Web of Science ®Google Scholar
• Baba Y, Saito B, Shimada S, et al. Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. Leuk Res. 2018;67:56–59. doi:10.1016/j.leukres.2018.02.00429433052
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884. doi:10.1182/blood-2013-05-50156923803709
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709. doi:10.1002/ajh.2579232239758
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Saußele S, Voskanyan A, Silver RT. Management of CML-blast crisis. Best Pract Res Clin Haematol. 2016;29(3):295–307. doi:10.1016/j.beha.2016.10.00527839570
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma. 2014;55(7):1451–1462. doi:10.3109/10428194.2013.84588324050507
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Mancini M, Martinelli G. Best practices in chronic myeloid leukemia monitoring and management. Oncologist. 2016;21(5):626–633. doi:10.1634/theoncologist.2015-033727032870
   PubMed Web of Science ®Google Scholar
• Bernardi S, Malagola M, Zanaglio C, et al. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med. 2019;8(5):2041–2055. doi:10.1002/cam4.208730950237
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Dulucq S, Boureau L, et al. Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients. Clin Cancer Res. 2019;25(22):6606–6613. doi:10.1158/1078-0432.CCR-18-337331292142
   PubMed Web of Science ®Google Scholar
• Furuya D, Moriai M, Koizumi Y, et al. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale. Int J Clin Oncol. 2019;24(7):871–875. doi:10.1007/s10147-019-01419-930798394
   PubMed Web of Science ®Google Scholar
• Dainiak N, Liu A, Dewey MC, Kulkarni V. Chromosome analysis of isolated colony erythroblasts in chronic myelogenous leukaemia. Br J Haematol. 1984;56(3):507–512. doi:10.1111/j.1365-2141.1984.tb03980.x6582926
   PubMed Web of Science ®Google Scholar
• Schmidt M, Rinke J, Schäfer V, et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014;28(12):2292–2299. doi:10.1038/leu.2014.27225212276
   PubMed Web of Science ®Google Scholar
• Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21):e198–e206. doi:10.1182/blood-2010-06-29243321346257
   PubMed Web of Science ®Google Scholar
• Iriyama N, Fujisawa S, Yoshida C, et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol. 2015;90(4):282–287. doi:10.1002/ajh.2392325530131
   PubMed Web of Science ®Google Scholar
• Mahon FX, Boquimpani C, Kim DW, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168(7):461–470. doi:10.7326/M17-109429459949
   PubMed Web of Science ®Google Scholar